Tirzepatide is a dual GIP/GLP-1 receptor agonist while semaglutide acts only on GLP-1 receptors
Recent clinical trials, published in September 2025 in The New England Journal of Medicine , show that high-dose oral semaglutide tablets can deliver weight loss results that begin to approach what we see with injections
Where it's most often discussed: Tissue repair and recovery models (especially tendons/ligaments and muscle) Wound healing and regenerative signaling Gut integrity and inflammation-related pathways Where it's not firmly established: Extensive, rigorous human studies designed to measure fat loss outcomes (fat mass, waist circumference, body fat percentage) That distinction matters
Subcutaneous (SC) Injections: Subcutaneous injections are administered just beneath the skin into the fatty tissue, usually in the abdomen or upper arm
Patients who should not receive BPC-157 include: those with active or recent malignancies (due to angiogenic concerns), pregnant or breastfeeding women (no reproductive toxicology data in humans), patients on anticoagulation therapy (theoretical bleeding risk from angiogenesis at ulcer sites), and minors (no pediatric data of any kind)
Many people pair peptide support with sleep optimization, hydration, protein intake, and smart training
